|
Jun 19
|
Is There An Opportunity With CSL Limited's (ASX:CSL) 39% Undervaluation?
|
|
Jun 16
|
U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start
|
|
Feb 14
|
Here's What Analysts Are Forecasting For CSL Limited (ASX:CSL) After Its Half-Yearly Results
|
|
Feb 14
|
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
|
|
Feb 13
|
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
|
|
Feb 12
|
BMRN vs. CSLLY: Which Stock Is the Better Value Option?
|
|
Jul 25
|
GMAB vs. CSLLY: Which Stock Is the Better Value Option?
|
|
Apr 2
|
CSL Limited (ASX:CSL) On An Uptrend: Could Fundamentals Be Driving The Stock?
|
|
Feb 5
|
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
|
|
Jan 16
|
Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options
|
|
Jan 10
|
Chinese Soccer Remains Terrible. It Says This Is Why.
|
|
Dec 21
|
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
|
|
Dec 21
|
CSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older
|
|
Nov 28
|
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
|
|
Aug 28
|
CSL Seqirus Announces Third U.S. Government Award in Relation to Influenza A(H5N8) Candidate Vaccine
|
|
Aug 28
|
Ferinject® granted upgraded recommendations in 2023 ESC heart failure guidelines
|
|
Jul 17
|
CSL Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2023/24 U.S. Season
|